generic semaglutide vs wegovy 2026: What US Patients Need to Know Consumer group presses U.S. to

Clinical data also indicate beneficial molecular effects of GLP-1 RAs, despite their potential to reduce muscle mass

Unfortunately, this compound exhibits low bioavailability and solubility (Vesely et al., 2021)

Read our full take on what's at stake for patients and providers below

News provided by Novo Nordisk May 07, 2026, 07:00 ET Eligible Medicare patients living with obesity will have access to Wegovy (semaglutide) injection and pill for a $50 monthly copay Wegovy offers adults living with obesity significant weight loss, along with diet and exercise, and is FDA-approved to lower the risk of major CV events such as death, heart attack, or stroke in adults living with obesity with known heart disease, a claim only Wegovy can make Novo Nordisk's participation in the Medicare GLP-1 Bridge expands patient access to authentic, FDA-approved Wegovy PLAINSBORO, N.J., May 7, 2026 /PRNewswire/ -- The Medicare GLP-1 Bridge will provide eligible Medicare beneficiaries living with obesity access to Wegovy (semaglutide) injection and tablets for a $50 monthly copay , beginning July 1, 2026, per yesterday's announcement from the Centers for Medicare & Medicaid Services (CMS)

Helps bone density

Changes appear subtle, not dramatic